These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 17292737

  • 1. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A, Erben P, Ernst T, Mueller MC.
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A.
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [Abstract] [Full Text] [Related]

  • 9. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 10. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G, Iacobucci I, Soverini S, Cilloni D, Saglio G, Pane F, Baccarani M.
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. BCR-ABL mutations in chronic myeloid leukemia.
    Ernst T, La Rosée P, Müller MC, Hochhaus A.
    Hematol Oncol Clin North Am; 2011 Oct; 25(5):997-1008, v-vi. PubMed ID: 22054731
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
    La Rosée P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ.
    Cancer Res; 2002 Dec 15; 62(24):7149-53. PubMed ID: 12499247
    [Abstract] [Full Text] [Related]

  • 17. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD.
    Nat Rev Cancer; 2007 May 15; 7(5):345-56. PubMed ID: 17457302
    [Abstract] [Full Text] [Related]

  • 18. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.
    Hochhaus A, La Rosée P.
    Leukemia; 2004 Aug 15; 18(8):1321-31. PubMed ID: 15215876
    [Abstract] [Full Text] [Related]

  • 19. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J, Priwitzerová M, Jarosová M, Indrák K, Faber E, Divoký V.
    Cas Lek Cesk; 2006 Aug 15; 145(5):377-82. PubMed ID: 16755775
    [Abstract] [Full Text] [Related]

  • 20. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, Komatsu N, Takaku F, Ozawa K.
    Stem Cells; 2003 Aug 15; 21(3):315-21. PubMed ID: 12743326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.